Drug Release Balloon, Drug Release Device and Endoscopic Assembly

Abstract

The present invention discloses a drug-releasing balloon, a drug-releasing device and an endoscopic assembly, relating to the technical field of endoscopes. The drug-releasing balloon includes: a balloon body, a dissolving layer and a drug carrier. The drug carrier is disposed on the surface of the balloon body through the dissolving layer, and the drug carrier is set to include a piercing end which can be used to pierce into an external medium. At the same time, the balloon body is set to be an inflatable structure. When the balloon body is in an inflated state, the piercing end is exposed outside the balloon body, and when the balloon body is in a contracted state, the piercing end is wrapped inside the balloon body. In this way, the piercing end of the drug carrier can be wrapped by the balloon body before reaching the designated position to avoid falling off, and after reaching the designated position, the balloon body is inflated so that the piercing end can cooperate with the external medium, solving the problem in the prior art that the drug on the balloon is likely to fall off before drug administration, making it difficult to deliver the drug to the designated position for treatment, resulting in poor treatment effects.

Description

Technical Field

[0001] The present invention relates to the field of endoscopes, and in particular to a drug - releasing balloon, a drug - releasing device, and an endoscopic assembly. Background Art

[0002] A uterine packing balloon is a medical device mainly for treating gynecological diseases such as uterine bleeding in women. It can be used to place the balloon inside the uterus, and expand the balloon to achieve the effect of expanding and compressing for hemostasis, and can also be used to deliver drugs through the balloon to the uterus for treating the endometrium or repairing the membrane layer.

[0003] However, coating the drug on the surface of the balloon easily results in an insecure connection between the drug and the balloon, causing the drug to fall off before the balloon is inserted into the uterus or during the process of inserting it into the uterus. When the balloon is in the uterus, the position of the drug changes, making it difficult to treat the designated position, and thus the treatment effect is poor. Summary of the Invention

[0004] The present invention discloses an endoscopic assembly and an endoscope to at least partially improve the above - mentioned technical problems.

[0005] To solve the above problems, the present invention adopts the following technical solutions:

[0006] On the one hand, an embodiment of the present application provides a drug - releasing balloon, including: a balloon body, a dissolving layer, and a drug carrier. An inner cavity is formed inside the balloon body, and the balloon body has a liquid inlet channel that penetrates the inner cavity and the outside. The dissolving layer is disposed on the surface of the balloon body and is in communication with the liquid inlet channel. The drug carrier has a piercing end and a connecting end, and the connecting end is connected to the dissolving layer. Wherein, the balloon body is configured such that when the balloon body is in an inflated state, the piercing end is exposed outside the balloon body, and when the balloon body is in a contracted state, the piercing end is wrapped inside the balloon body.

[0007] In one embodiment, the balloon body includes a connected bearing part and a winding part. The connecting end is connected to the bearing part, and the winding part has a deformation ability. When the balloon body is in an inflated state, the piercing end is exposed outside the winding part, and when the balloon body is in a contracted state, the piercing end is wrapped inside the winding part.

[0008] In one embodiment, the dissolving layer is connected to the connecting end and extends beyond the connecting end to be connected to the balloon body. The dissolving layer, the connecting end, and the balloon body together enclose a dissolving cavity, and the liquid inlet channel is in communication with the dissolving cavity.

[0009] In one embodiment, the liquid inlet channel is disposed near the edge of the dissolving cavity.

[0010] In one embodiment, a plurality of liquid inlet channels are provided, and the plurality of liquid inlet channels are evenly distributed and communicate with the dissolution chamber.

[0011] In one embodiment, the carrying part is provided with a mounting groove, and the drug carrier is arranged in the mounting groove.

[0012] In one embodiment, the piercing end includes at least one conical structure.

[0013] On the other hand, an embodiment of the present application further provides a drug delivery device, including a tube body and the drug delivery balloon as described above. The distal end of the tube body communicates with the inner cavity, and the distal end of the tube body is hermetically connected to the inner cavity. The tube body is used to inject liquid into the inner cavity.

[0014] In one embodiment, the distal end of the tube body has a reduced diameter region, and the radial dimension of the reduced diameter region is smaller than the radial dimension of the proximal end of the tube body. The inner cavity is hermetically connected to the reduced diameter region.

[0015] In still another aspect, an embodiment of the present application further provides an endoscopic assembly, including an endoscope and the drug delivery device as described above. The endoscope has an instrument channel, and the drug delivery device is detachably arranged in the instrument channel.

[0016] The technical solution adopted by the present invention can achieve the following beneficial effects:

[0017] The drug delivery balloon provided by the embodiment of the present application arranges the drug carrier on the surface of the balloon body through the dissolution layer, and the drug carrier is set to include a piercing end, which can be used to pierce into an external medium, for example, it can pierce into the endometrium. At the same time, the balloon body is set as an expandable structure. When the balloon body is in an expanded state, the piercing end is exposed outside the balloon body. When the balloon body is in a contracted state, the piercing end is wrapped inside the balloon body. In this way, the piercing end of the drug carrier can be wrapped by the balloon body before reaching the designated position to avoid falling off. After reaching the designated position, the balloon body is inflated so that the piercing end can cooperate with the external medium, and the dissolution layer can be dissolved by the dissolution liquid injected into the balloon body to make the balloon body expand. Furthermore, the drug carrier can fall off from the balloon body, solving the problem in the prior art that the drug on the balloon is easy to fall off before drug administration, and it is difficult to deliver the drug to the designated position for treatment, resulting in poor treatment effects. Applying the above drug delivery balloon to the drug delivery device can also solve the above problems. Applying the above drug delivery device to the endoscopic assembly can also solve the above problems. Description of the Drawings

[0018] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for use in the description of the embodiments or the prior art. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0019] Figure 1 The structural schematic diagram shows a cyst in a contracted state in an endoscopic assembly according to an embodiment of the present application;

[0020] Figure 2 The structural schematic diagram shows a cyst in an inflated state in an endoscopic assembly according to an embodiment of the present application;

[0021] Figure 3 The structural schematic diagram shows a cyst in a contracted state after an endoscopic assembly extends into the uterus according to an embodiment of the present application;

[0022] Figure 4 The structural schematic diagram shows a cyst in an inflated state after an endoscopic assembly extends into the uterus according to an embodiment of the present application;

[0023] Figure 5 For Figure 1 The enlarged view of part A in

[0024] Figure 6 The cross-sectional view shows a partial structure of an endoscopic assembly according to an embodiment of the present application;

[0025] Figure 7 The partial structural schematic diagram shows a cyst in a contracted state in a drug-releasing balloon according to an embodiment of the present application;

[0026] Figure 8 The structural schematic diagram shows a cyst in an inflated state and in contact with the endometrium in a drug-releasing balloon according to an embodiment of the present application;

[0027] Figure 9 For Figure 8 The enlarged view of part B in

[0028] In the figure: 1. Endoscopic assembly; 10. Drug release device; 110. Drug release balloon; 111. Cyst; 1111. Inner cavity; 1112. Liquid inlet channel; 1113. Bearing part; 1114. Winding part; 1115. Installation groove; 112. Dissolving layer; 1121. Dissolving cavity; 113. Drug carrier; 1131. Piercing end; 1132. Connection end; 120. Tube body; 121. Narrowing area; 20. Endoscope; 210. Instrument channel; 220. Liquid injection channel; 2. Uterus. Detailed implementation manners

[0029] To make the objectives, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be described in detail below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other implementation manners obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts belong to the scope protected by the present invention.

[0030] The terms "first", "second", etc. in the specification and claims of this application are used to distinguish similar objects, rather than to describe a specific order or sequence. It should be understood that such used data can be interchanged under appropriate circumstances so that the embodiments of this application can be implemented in an order other than those illustrated or described herein, and the objects distinguished by "first", "second", etc. are usually of the same type, and the number of objects is not limited. For example, the first object can be one or multiple. In addition, "and / or" in the specification and claims means at least one of the connected objects, and the character " / ", generally represents an "or" relationship between the associated objects before and after.

[0031] In the embodiments of this application, "proximal end" and "distal end" refer to the relative distances of each component from the user in the usage environment. Among them, the end closer to the user is designated as the "proximal end", and the end farther from the user is designated as the "distal end".

[0032] The inventive concept of this application is described here:

[0033] The uterine packing balloon is a medical device mainly for treating gynecological diseases such as uterine bleeding in women. It can be used to place the balloon inside the uterus and expand the balloon to achieve the effect of expanding and compressing bleeding, and can also be used to deliver drugs through the balloon to the uterus for treating or repairing the endometrium.

[0034] However, when the drug is coated on the surface of the balloon, it is easy to have an insecure connection between the drug and the balloon, resulting in the drug falling off before the balloon is inserted into the uterus or during the process of inserting the balloon into the uterus. When the balloon is located in the uterus, the position of the drug changes, making it difficult to treat the designated position, and thus the treatment effect is not good. If the method of injecting the drug at a fixed point is adopted, although this can ensure that the drug can fully contact the endometrium, this method not only has a small action range, but also is very complicated to operate.

[0035] Based on this, the inventors provide a drug - releasing balloon, a drug - releasing device, and an endoscopic assembly. The drug - releasing balloon can be configured to have a structure in which a dissolution layer connects a drug carrier and a balloon body. The balloon body is configured such that when the balloon body is in an inflated state, the insertion end of the drug carrier is exposed outside the balloon body, so as to facilitate contact between the drug carrier and the target medium and perform treatment on it. After the drug carrier is inserted into the target medium, the dissolution layer can be injected into the balloon body and dissolved by a dissolution liquid that causes the balloon body to expand, thereby detaching the drug carrier from the balloon body to perform a drug - application operation on the target medium. When the balloon body is in a contracted state, the insertion end of the drug carrier is wrapped inside the balloon body to prevent the drug carrier from falling off due to the influence of the external environment before drug - application to the target medium, which may affect subsequent drug - application to the target medium.

[0036] The following combines the attached Figures 1 to 9 , and through specific embodiments and their application scenarios, a drug - releasing balloon 110, a drug - releasing device 10, and an endoscopic assembly 1 provided by the present application are described in detail.

[0037] Please refer to Figures 1 - 4 simultaneously. An endoscopic assembly 1 is provided in an embodiment of the present application. The endoscopic assembly 1 can be used to apply drugs to the endometrium to treat or repair the endometrium. The endoscopic assembly 1 can include: an endoscope 20 and a drug - releasing device 10. The endoscope 20 can serve as a carrier for the drug - releasing device 10. The drug - releasing device 10 is sent into the uterus 2 through the endoscope 20, and the drug - releasing device 10 is used to attach drugs to the endometrium.

[0038] Please refer to Figure 1 and Figure 5 simultaneously. The endoscope 20 can have an instrument channel 210 and a liquid - injection channel 220. The instrument channel 210 can be used to accommodate the drug - releasing device 10, and the liquid - injection channel 220 can communicate with the drug - releasing device 10. In this embodiment, the drug - releasing device 10 is detachably arranged in the instrument channel 210 so that the endoscope 20 can be reused.

[0039] Please refer to Figure 1 , Figure 5 and Figure 6, the drug delivery device 10 may include: a tube body 120 and a drug delivery balloon 110. The distal end of the tube body 120 may communicate with the drug delivery balloon 110, and the distal end of the tube body 120 may be sealingly connected to the inner cavity 1111. The tube body 120 may communicate with the liquid injection channel 220. The operator may inject liquid into the tube body 120 through the liquid injection channel 220, so that the dissolution solution enters the drug delivery balloon 110. The dissolution solution injected into the drug delivery balloon 110 is not limited in the embodiments of the present application. For example, it may be normal saline or the like. After the drug delivery balloon 110 is injected with the dissolution solution, it will expand, and then the drug can contact the target medium, such as the endometrium, and then perform targeted treatment on the target medium.

[0040] Please continue to refer to Figure 6 , in one embodiment, the distal end of the tube body 120 may have a necked-down region 121. The radial dimension of the necked-down region 121 may be smaller than the radial dimension of the proximal end of the tube body 120. The drug delivery balloon 110 may be sealingly connected to the necked-down region 121. This can make the dimensions of each part of the entire drug delivery device 10 tend to be consistent, and avoid the distal end of the drug delivery device 10 becoming larger in size after connecting the drug delivery balloon 110, resulting in difficulty in smoothly moving in the instrument channel 210.

[0041] Furthermore, in some embodiments, the tube body 120 may extend into the interior of the drug delivery balloon 110. It can be understood that since the drug delivery balloon 110 has a low structural strength and is prone to collapse when in a contracted state, extending the tube body 120 into the interior of the drug delivery balloon 110 can make the tube body 120 serve as a support structure for the drug delivery balloon 110. This can facilitate the insertion of the drug delivery device 10 into the uterus 2, and at the same time, during the process of inserting into the uterus 2, the tube body 120 can also play a guiding role.

[0042] Please refer to Figure 7 , the drug delivery balloon 110 may include: a balloon body 111, a dissolution layer 112, and a drug carrier 113. An inner cavity 1111 is formed inside the balloon body 111, and the balloon body 111 also has a liquid inlet channel 1112 that penetrates the inner cavity 1111 and the outside. As described above, the tube body 120 may extend into the inner cavity 1111 and inject liquid into the inner cavity 1111.

[0043] Specifically, in this embodiment, the balloon body 111 may be arranged such that when the balloon body 111 is in an expanded state, the drug carrier 113 may be exposed outside the balloon body 111, and when the balloon body 111 is in a contracted state, the drug carrier 113 may be wrapped inside the balloon body 111. This can not only prevent the drug carrier 113 from falling off before drug administration, but also ensure that the drug carrier 113 can cooperate well with the target medium during the drug administration process.

[0044] The dissolving layer 112 can be disposed on the surface of the capsule 111 and communicated with the liquid inlet channel 1112. In a preferred embodiment, the dissolving layer 112 can be located at the channel opening of the liquid inlet channel 1112, so that the dissolving liquid in the liquid inlet channel 1112 can contact the dissolving layer 112 for the first time and promote the dissolution of the dissolving layer 112. The embodiment of the present application does not limit the specific form of the dissolving layer 112. For example, in an embodiment, the dissolving layer 112 can be gelatin, starch, sodium alginate or chitosan, etc., which can be set according to actual conditions.

[0045] The drug carrier 113 may have an insertion end 1131 and a connection end 1132, the connection end 1132 may be connected to the dissolving layer 112, the insertion end 1131 may be arranged outward away from the capsule 111, and the insertion end 1131 may be used to be inserted into and fixed to the target medium. As mentioned above, when the capsule 111 is in an expanded state, the insertion end 1131 may be exposed outside the capsule 111, and the insertion end 1131 may be inserted into and fixed to the target medium. At the same time, the dissolving liquid injected into the capsule 111 may contact the dissolving layer 112 through the liquid inlet channel 1112, so that the dissolving layer 112 is dissolved, and the drug carrier 113 will be separated from the capsule 111, thereby fixing the drug carrier 113 to the target medium and accurately treating the target medium.

[0046] In one embodiment, the insertion end 1131 may include at least one conical structure, so that the insertion end 1131 can be inserted into the target medium more conveniently and stably. The embodiment of the present application does not limit the specific form and number of the conical structure. For example, the outer surface of the conical structure can be set to a curved structure similar to a snake, and the number of conical structures can be set to two or three, etc., which can be set according to actual conditions and are not limited here.

[0047] The drug carrier 113 can carry drugs, and when the insertion end 1131 is fixed to the target medium, the drug can accurately treat the target medium. It should be noted that in some embodiments, the drug carrier 113 can be composed of drugs, and in other embodiments, it can also be composed of drugs and porous carriers. In this embodiment, the porous carrier can be an inorganic carrier, such as silicon dioxide, aluminum hydroxide, etc. For example, in another embodiment, the porous carrier can also be an organic carrier, such as polyester, polyamide, polyorthoester, polyethylene oxide, polyamide ester, etc., which can be set according to actual conditions and are not limited here.

[0048] Please also see Figures 7 - 9, in one embodiment, the bladder 111 may include a connected bearing portion 1113 and a winding portion 1114. The connecting end 1132 may be connected to the bearing portion 1113. The winding portion 1114 may have a deformation ability. When the bladder 111 is in an inflated state, the piercing end 1131 may be exposed outside the winding portion 1114. When the bladder 111 is in a contracted state, the piercing end 1131 may be wrapped inside the winding portion 1114. The embodiments of the present application do not limit the winding and unfolding methods of the winding portion 1114. For example, in one embodiment, the winding portion 1114 may approach the bearing portion 1113 during the winding process and wrap the bearing portion 1113.

[0049] Please refer to Figure 9 , further, in one embodiment, the bearing portion 1113 may be provided with an installation groove 1115. The drug carrier 113 may be disposed in the installation groove 1115. The setting of the installation groove 1115 may further improve the connection stability between the drug carrier 113 and the bladder 111, and prevent the drug carrier 113 from detaching from the bladder 111 before drug administration.

[0050] In a more specific embodiment, the bearing portion 1113 may also be configured to have a deformation ability, that is, when the bladder 111 is in an inflated state, the bearing portion 1113 will also expand accordingly, and the size of the installation groove 1115 will increase. At this time, the drug carrier 113 located in the installation groove 1115 may naturally detach from the installation groove 1115. When the bladder 111 is in a contracted state, the bearing portion 1113 will also contract accordingly, and the size of the installation groove 1115 will decrease. At this time, the drug carrier 113 located in the installation groove 1115 may be clamped by the installation groove 1115, thereby improving the connection stability between the drug carrier 113 and the bladder 111, and preventing the drug carrier 113 from detaching from the bladder 111 before drug administration. That is to say, in this embodiment, the drug release balloon 110 can not only avoid the risk of the drug carrier 113 detaching before drug administration, but also facilitate drug administration.

[0051] In addition, in one embodiment, the dissolving layer 112 may be connected to the connecting end 1132 and extend out of the connecting end 1132 to be connected to the bladder 111. The dissolving layer 112, the connecting end 1132, and the bladder 111 together enclose a dissolving cavity 1121. The liquid inlet channel 1112 is communicated with the dissolving cavity 1121. That is to say, in this embodiment, the dissolving layer 112 may be a hollow structure, which can not only reduce costs, but also enable the dissolving layer 112 to be dissolved faster, avoiding discomfort to the patient caused by the drug release balloon 110 being in an inflated state for a long time.

[0052] Further, in one embodiment, the liquid inlet channel 1112 may be disposed near the edge of the dissolution chamber 1121, so that the dissolution layer 112 can come into contact with the dissolution liquid faster, and thus the dissolution layer 112 can be dissolved faster.

[0053] It can be understood that, in some other embodiments, there may be multiple liquid inlet channels 1112, and the multiple liquid inlet channels 1112 can be evenly distributed and communicate with the dissolution chamber 1121, so that the dissolution layer 112 can also come into contact with the dissolution liquid faster, and thus the dissolution layer 112 can be dissolved faster.

[0054] In summary, for the drug release balloon 110 provided in the embodiment of the present application, the drug carrier 113 is disposed on the surface of the balloon body 111 through the dissolution layer 112, and the drug carrier 113 is set to include a piercing end 1131, and the piercing end 1131 can be used to pierce into an external medium, for example, it can pierce into the endometrium. At the same time, the balloon body 111 is set to be an inflatable structure. When the balloon body 111 is in an inflated state, the piercing end 1131 is exposed outside the balloon body 111. When the balloon body 111 is in a contracted state, the piercing end 1131 is wrapped inside the balloon body 111. In this way, the piercing end 1131 of the drug carrier 113 can be wrapped by the balloon body 111 to avoid falling off before reaching the designated position. After reaching the designated position, the balloon body 111 is inflated so that the piercing end 1131 can cooperate with the external medium, and the dissolution layer 112 can be dissolved by the dissolution liquid injected into the balloon body 111 to inflate the balloon body 111, and thus the drug carrier 113 can fall off from the balloon body 111, solving the problem in the prior art that the drug on the balloon is likely to fall off before drug administration, making it difficult to deliver the drug to the designated position for treatment, resulting in poor treatment effects. Applying the above-mentioned drug release balloon 110 to the drug release device 10 can also solve the above problems. Applying the above-mentioned drug release device 10 to the endoscopic assembly 1 can also solve the above problems.

[0055] It should be noted that, in this article, the terms "include", "comprise" or any other variant thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements not only includes those elements, but also includes other elements not expressly listed, or further includes elements inherent to such process, method, article or device. Without further limitation, an element defined by the phrase "including one..." does not exclude the existence of additional identical elements in the process, method, article or device including the element.

[0056] In addition, it should be noted that the scope of the methods and apparatuses in the embodiments of the present application is not limited to performing functions in the order shown or discussed, and may also include performing functions in a substantially simultaneous manner or in a reverse order according to the functions involved. For example, the described methods may be performed in an order different from that described, and various steps may also be added, omitted, or combined. Additionally, the features described with reference to certain examples may be combined in other examples.

[0057] As described above, the foregoing are only specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art within the technical scope disclosed by the present invention can easily conceive of changes or substitutions, which should all be covered within the protection scope of the present invention.

Claims

1. A drug releasing balloon, characterized in that: include: A capsule body, wherein an inner cavity is formed inside the capsule body, and the capsule body has a liquid inlet channel penetrating the inner cavity and the outside; a dissolving layer, the dissolving layer being disposed on the surface of the capsule and communicating with the liquid inlet channel; and A drug carrier, the drug carrier having an insertion end and a connection end, the connection end being connected to the dissolution layer; Wherein, the sac is configured such that when the sac is in an expanded state, the insertion end is exposed outside the sac, and when the sac is in a contracted state, the insertion end is wrapped inside the sac.

2. The drug-releasing balloon according to claim 1, characterized in that: The sac body includes: a load-bearing portion and a rolling portion which are connected to each other, the connecting end is connected to the load-bearing portion, the rolling portion has deformation capability, when the sac body is in an expanded state, the insertion end is exposed outside the rolling portion, when the sac body is in a contracted state, the insertion end is wrapped inside the rolling portion.

3. The drug-releasing balloon according to claim 2, characterized in that: The dissolution layer is connected to the connection end and extends out of the connection end to be connected to the capsule body. The dissolution layer, the connection end and the capsule body together form a dissolution cavity, and the liquid inlet channel is communicated with the dissolution cavity.

4. The drug-releasing balloon according to claim 3, characterized in that: The liquid inlet channel is arranged close to the edge of the dissolution chamber.

5. The drug-releasing balloon according to claim 3, characterized in that: The liquid inlet channels are provided with a plurality of them, and the plurality of liquid inlet channels are evenly distributed and connected to the dissolution chamber.

6. The drug-releasing balloon according to any one of claims 2 to 5, characterized in that: The bearing portion is provided with a mounting groove, and the drug carrier is arranged in the mounting groove.

7. The drug-releasing balloon according to claim 1, characterized in that: The insertion end includes at least one cone-shaped structure.

8. A drug release device, characterized in that: include: A tube body and a drug-releasing balloon as claimed in any one of claims 1 to 7, wherein the distal end of the tube body is communicated with the inner cavity, and the distal end of the tube body is sealedly connected to the inner cavity, and the tube body is used to inject liquid into the inner cavity.

9. The drug release device according to claim 8, characterized in that: The distal end of the tube body has a constricted area, the radial dimension of the constricted area is smaller than the radial dimension of the proximal end of the tube body, and the inner cavity is sealingly connected to the constricted area.

10. An endoscope assembly, characterized in that: It comprises an endoscope and a drug releasing device as described in any one of claims 8 to 9, wherein the endoscope has an instrument channel, and the drug releasing device is detachably disposed in the instrument channel.

Images